Northwestern University Human Resources

FORESEE trial of CNSide CSF Assay met primary and secondary endpoints, influencing clinical decisions in over 90% of leptomeningeal metastases cases and demonstrating 2.8 times the diagnostic sensitivity vs. standard cytology.

Umoja Biopharma appoints Scott Myers as Chairman of its Board of Directors, succeeding Dieter Weinand who will remain as an advisor. Myers, with extensive biotech experience, aims to transform CAR-T cell therapy delivery.

EchoGo® Amyloidosis, an AI-powered tool, aids in detecting Cardiac Amyloidosis with 84.5% sensitivity and 89.7% specificity, supported by Janssen and Pfizer. Early detection is crucial for therapeutic benefits, addressing diagnostic challenges in underdiagnosed conditions.

Covid-induced immune cells can attack cancer, showing promise in treating melanoma, lung, breast, and colon cancers, with animal model tests reducing tumours by 60-70%. Clinical trials are needed for further validation.

Samuel Simmons, with ichthyosis, spends hours daily scrubbing dry, scaly skin. Research for a cure is slow, with dermatologists repurposing drugs for other skin conditions. Ichthyosis, a family of genetic skin diseases, causes skin cell turnover issues, leading to dry, cracked skin. Despite some progress with retinoids, a cure remains elusive. Dermatologists like Amy Paller and Joyce Teng are exploring immunomodulatory drugs used for psoriasis, revealing shared immune signatures. Clinical trials with IL-17-targeting drugs have shown mixed results, highlighting the need for personalized treatments due to ichthyosis's diversity. Simmons, frustrated but hopeful, keeps an eye on ongoing research.

Mitiperstat, a myeloperoxidase inhibitor, showed no significant improvement in quality of life or functional capacity in heart failure patients with mid-range to preserved ejection fraction in the ENDEAVOR trial. However, it reduced heart failure hospitalizations by 36%, suggesting further exploration in larger trials.

Alzheimer’s affects 6M Americans, projected to double by 2050. Early detection is crucial for quality of life, but 33-44M with dementia remain undiagnosed. Innovations like blood tests for pTau217 offer scalable, accessible early diagnosis, paving the way for personalized medicine and improved care outcomes.

Tempus AI, Inc. (NASDAQ:TEM) saw a 19.2% increase in short interest to 3,470,000 shares by October 31st, with a days-to-cover ratio of 3.0 days. Institutional investors like Alphabet Inc. and ARK Investment Management LLC bought new stakes in the company during Q2. Analysts have mixed ratings, with a consensus 'Moderate Buy' and an average target price of $54.22. Shares traded down $4.23 on Friday, reaching $52.40.